HAEMONETICS CORP - Common Stock (HAE)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
HAE on NYSE
Shares outstanding
47,898,935
Price per share
$48.74
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
51,316,369
Total reported value
$2,500,012,174
% of total 13F portfolios
0%
Share change
-2,935,220
Value change
-$235,189,916
Number of holders
295
Price from insider filings
$80.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HAEMONETICS CORP - Common Stock (HAE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 4.6% -16% $165,537,761 -$36,448,193 2,203,351 -18% Wellington Management Group LLP 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.4% $135,949,632 2,195,569 T. Rowe Price Investment Management, Inc. 31 Mar 2025
Capital Research Global Investors 3.1% $97,667,840 1,577,323 Capital Research Global Investors 31 Mar 2025
As of 30 Sep 2025, HAEMONETICS CORP - Common Stock (HAE) has 295 institutional shareholders filing 13F forms. They hold 51,316,369 shares. .

Top 25 institutional shareholders own 76% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 6,020,678 -5.4% 0.01% $293,447,860
VANGUARD GROUP INC 10% 4,834,646 -2.4% 0% $235,640,646
NEUBERGER BERMAN GROUP LLC 7.7% 3,670,282 -14% 0.13% $178,870,818
AQR CAPITAL MANAGEMENT LLC 4.4% 2,128,878 +373% 0.07% $102,814,162
STATE STREET CORP 3.8% 1,800,729 -4.4% 0% $87,767,531
River Road Asset Management, LLC 3.5% 1,654,790 -0.05% 0.9% $80,654,465
UBS Group AG 3% 1,452,571 +67% 0.01% $70,798,310
ROYAL BANK OF CANADA 2.6% 1,260,820 +16% 0.01% $61,451,000
FMR LLC 2.5% 1,215,829 +45% 0% $59,259,529
GEODE CAPITAL MANAGEMENT, LLC 2.5% 1,203,380 -3.3% 0% $58,660,306
DIMENSIONAL FUND ADVISORS LP 2.3% 1,099,519 +2.5% 0.01% $53,587,050
Allspring Global Investments Holdings, LLC 2.2% 1,060,790 +12% 0.08% $51,777,160
T. Rowe Price Investment Management, Inc. 2.1% 1,010,957 -37% 0.03% $49,275,000
Boston Trust Walden Corp 2% 956,690 -12% 0.34% $46,629,071
MILLENNIUM MANAGEMENT LLC 1.6% 773,179 +1957% 0.03% $37,684,744
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ 1.5% 706,312 +36% 0.19% $34,425,647
ROYCE & ASSOCIATES LP 1.5% 701,242 -45% 0.34% $34,178,535
Fisher Asset Management, LLC 1.4% 662,504 -3.9% 0.01% $32,290,444
SILVERCREST ASSET MANAGEMENT GROUP LLC 1.3% 641,622 +7.2% 0.21% $31,272,775
FRANKLIN RESOURCES INC 1.3% 627,231 +2% 0.01% $30,571,250
NORTHERN TRUST CORP 1.3% 602,378 -5.2% 0% $29,359,903
GOLDMAN SACHS GROUP INC 1.2% 582,754 -9.6% 0% $28,403,430
Boston Partners 1.2% 570,891 +5.1% 0.03% $28,016,562
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.2% 561,812 -0.06% 0% $27,382,717
BARROW HANLEY MEWHINNEY & STRAUSS LLC 1.2% 559,972 +16% 0.09% $27,293,035

Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 235,138 $18,861,330 -$9,136,891 $80.15 11
2025 Q3 51,316,369 $2,500,012,174 -$235,189,916 $48.74 295
2025 Q2 54,253,774 $4,048,407,950 +$51,089,014 $74.61 297
2025 Q1 53,724,229 $3,412,895,600 -$212,763,194 $63.55 313
2024 Q4 56,558,011 $4,415,683,452 +$40,389,204 $78.08 305
2024 Q3 55,858,330 $4,486,624,929 -$21,003,128 $80.38 303
2024 Q2 55,851,715 $4,621,294,419 +$385,980,667 $82.73 315
2024 Q1 51,176,074 $4,367,618,453 +$50,781,270 $85.35 296
2023 Q4 50,568,886 $4,325,205,912 -$20,996,057 $85.51 294
2023 Q3 50,792,206 $4,551,407,114 +$20,351,169 $89.58 294
2023 Q2 50,542,703 $4,303,570,562 +$14,249,115 $85.14 288
2023 Q1 50,384,868 $4,169,004,070 +$9,612,280 $82.75 294
2022 Q4 50,382,562 $3,963,254,277 -$107,357,997 $78.65 287
2022 Q3 51,775,808 $3,833,648,345 -$28,085,090 $74.03 260
2022 Q2 52,080,593 $3,394,785,256 +$49,689,135 $65.18 229
2022 Q1 51,567,377 $3,257,869,910 +$120,748,445 $63.22 225
2021 Q4 50,084,803 $2,655,680,021 -$87,203,336 $53.04 240
2021 Q3 50,697,310 $3,576,779,438 +$7,330,940 $70.59 239
2021 Q2 50,672,122 $3,375,443,272 -$52,557,812 $66.64 249
2021 Q1 49,961,531 $5,549,106,460 -$22,300,347 $111.01 288
2020 Q4 49,701,181 $5,902,338,582 +$13,637,273 $118.75 278
2020 Q3 49,419,749 $4,312,359,704 -$6,823,951 $87.25 261
2020 Q2 49,513,911 $4,436,797,359 -$134,065,133 $89.56 276
2020 Q1 50,595,124 $5,040,192,796 +$54,162,521 $99.66 263
2019 Q4 49,844,997 $5,726,892,199 -$8,413,468 $114.90 291
2019 Q3 49,617,874 $6,258,106,643 -$157,378,824 $126.14 271
2019 Q2 50,896,394 $6,124,009,590 +$58,035,871 $120.34 253
2019 Q1 51,283,498 $4,486,016,605 +$62,307,595 $87.48 253
2018 Q4 50,443,395 $5,047,277,313 -$147,988,434 $100.05 277
2018 Q3 51,715,308 $5,924,362,043 +$210,608,325 $114.58 289
2018 Q2 50,368,130 $4,517,192,617 -$185,243,709 $89.68 289
2018 Q1 52,583,034 $3,847,182,644 +$17,637,230 $73.16 254
2017 Q4 53,625,853 $3,115,125,238 -$26,066,940 $58.08 240
2017 Q3 54,786,766 $2,458,102,091 -$29,442,951 $44.87 203
2017 Q2 55,471,370 $2,190,580,845 +$31,076,045 $39.49 190
2017 Q1 54,635,388 $2,216,655,714 +$337,134,900 $40.57 176
2016 Q4 52,451,093 $2,108,521,648 +$26,285,233 $40.20 192
2016 Q3 51,805,572 $1,875,274,739 +$32,082,627 $36.21 176
2016 Q2 50,973,144 $1,478,067,581 -$32,032,171 $28.99 169
2016 Q1 51,250,356 $1,791,862,985 +$9,515,385 $34.98 160
2015 Q4 51,190,608 $1,650,317,369 -$35,481,356 $32.24 158
2015 Q3 52,124,856 $1,684,666,056 -$42,369,690 $32.32 168
2015 Q2 53,401,411 $2,208,658,190 -$15,026,392 $41.36 176
2015 Q1 53,751,288 $2,413,804,087 -$14,774,340 $44.92 166
2014 Q4 54,180,608 $2,027,372,717 +$29,529,104 $37.42 171
2014 Q3 53,079,424 $1,853,545,493 -$47,792,045 $34.92 168
2014 Q2 54,462,831 $1,921,442,064 +$18,983,073 $35.28 172
2014 Q1 54,173,562 $1,765,475,443 -$102,994,220 $32.59 187